Quanterix (NASDAQ:QTRX) is preparing to release its quarterly earnings on Monday, 2026-03-02. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Quanterix to report an earnings per share (EPS) of $-0.40.

Investors in Quanterix are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Past Earnings Performance

Last quarter the company beat EPS by $0.06, which was followed by a 2.34% drop in the share price the next day.

Here's a look at Quanterix's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.41	-0.41	-0.69	-0.22
EPS Actual	-0.35	-0.47	-0.53	-0.30
Price Change %	-2.34	-13.79	-19.02	-1.79

Stock Performance

Shares of Quanterix were trading at $6.72 as of February 26. Over the last 52-week period, shares are down 7.69%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

All You Need to Know About Quanterix

Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

Quanterix: Delving into Financials

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Quanterix displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 13.38%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Quanterix's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -83.48% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Quanterix's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.04%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.18%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.13, Quanterix adopts a prudent financial strategy, indicating a balanced approach to debt management.

To track all earnings releases for Quanterix visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.